Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for Heparin-Induced Thrombocytopenia
NCT01598168Phase 3Terminated
- Sponsor
- McMaster University
- Start
- Jan 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rivaroxaban in heparin-induced thrombocytopenia (HIT), sponsored by McMaster University. Primary endpoint: Incidence of new symptomatic venous and arterial thromboembolism in the study population at 30 days. Started Jan 2013; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT01598168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01598168.